Key substance use and mental health indicators in the United States: results from the 2023 National Survey on Drug Use and Health (HHS Publication No. PEP24-07-021, NSDUH Series H-59). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration https://www.samhsa.gov/data/sites/default/files/reports/rpt47095/National%20Report/National%20Report/2023-nsduh-annual-national.pdf (2025).
Schwartz, R. P. et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. Am. J. Public Health 103, 917–922 (2013).
Compton, W. M. & Volkow, N. D. Extended-release buprenorphine and its evaluation with patient-reported outcomes. JAMA Netw. Open 4, e219708 (2021).
Koob, G. F. & Le Moal, M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24, 97–129 (2001).
Koob, G. F. Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement. Biol. Psychiatry 87, 44–53 (2020).
Koob, G. F. & Volkow, N. D. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiat. 3, 760–773 (2016).
Moeller, S. J. & Goldstein, R. Z. Impaired self-awareness in human addiction: deficient attribution of personal relevance. Trends Cogn. Sci. 18, 635–641 (2014).
Zhang, R. & Volkow, N. D. Brain default-mode network dysfunction in addiction. Neuroimage 200, 313–331 (2019).
Kalivas, P. W. The glutamate homeostasis hypothesis of addiction. Nat. Rev. Neurosci. 10, 561–572 (2009).
Kiluk, B. D., Yip, S. W., DeVito, E. E., Carroll, K. M. & Sofuoglu, M. Anhedonia as a key clinical feature in the maintenance and treatment of opioid use disorder. Clin. Psychol. Sci. 7, 1190–1206 (2019).
Moningka, H. et al. Can neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research. Neuropsychopharmacol 44, 259–273 (2019).
Krystal, J. H., Kavalali, E. T. & Monteggia, L. M. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology 49, 41–50 (2024).
Krystal, J. H. et al. Ketamine and the neurobiology of depression: toward next-generation rapid-acting antidepressant treatments. Proc. Natl Acad. Sci. USA 120, e2305772120 (2023).
Dakwar, E. et al. A single ketamine infusion combined with mindfulness-based behavioral modification to treat cÿocaine dependence: a randomized clinical trial. Am. J. Psychiatry 176, 923–930 (2019).
Grabski, M. et al. Adjunctive ketamine with relapse prevention–based psychological therapy in the treatment of alcohol use Disorder. Am. J. Psychiatry 179, 152–162 (2022).
Walsh, Z. et al. Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open 8, e19 (2022).
Krupitsky, E. et al. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J. Subst. Abuse Treat. 23, 273–283 (2002).
Kelson, M., Burnett, J. M., Matthews, A. & Juneja, T. Ketamine treatment for alcohol use disorder: a systematic review. Cureus https://www.cureus.com/articles/117207-ketamine-treatment-for-alcohol-use-disorder-a-systematic-review.pdf (2025).
Tran, K. & MacDougall, D. Ketamine for adults with substance use disorders. Can. J. Health Technol. https://doi.org/10.51731/cjht.2024.845 (2025).
Nardou, R. et al. Psychedelics reopen the social reward learning critical period. Nature https://doi.org/10.1038/s41586-023-06204-3 (2023).
Wu, H., Savalia, N. K. & Kwan, A. C. Ketamine for a boost of neural plasticity: how, but also when?. Biol. Psychiatry 89, 1030–1032 (2021).
Kopelman, J. et al. Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression. Transl. Psychiatry 13, 159 (2023).
Scheidegger, M. et al. Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoS ONE 7, e44799 (2012).
Marguilho, M., Figueiredo, I. & Castro-Rodrigues, P. A unified model of ketamine’s dissociative and psychedelic properties. J. Psychopharmacol. 37, 14–32 (2023).
Mollaahmetoglu, O. M. et al. ‘This is something that changed my life’: a qualitative study of patients’ experiences in a clinical trial of ketamine treatment for alcohol use disorders. Front. Psychiatry 12, 695335 (2021).
Terasaki, D. Acute subjective experiences of intravenous ketamine therapy among medically hospitalized patients with alcohol use disorder. Psychedelic Med. 2, 116–126 (2024).
Petrovitch, D. et al. Qualitative analysis of a patient’s experience of ketamine-assisted psychotherapy for substance use disorder: Empirical synergies with twelve-step programs. Psychiatry Res. Case Rep. 4, 100259 (2025).
Garland, E. L. Mindfulness-Oriented Recovery Enhancement: An Evidence-Based Treatment for Chronic Pain and Opioid Use (Guilford Press, 2024).
Garland, E. L. Mindfulness-oriented recovery enhancement: implementing an evidence-based intervention for chronic pain, opioid use, and opioid addiction in clinical settings. Br. J. Clin. Pharmacol. 90, 3028–3035 (2024).
Garland, E. L. et al. Mindfulness-oriented recovery enhancement vs supportive group therapy for co-occurring opioid misuse and chronic pain in primary care: a randomized clinical trial. JAMA Intern. Med. 182, 407–417 (2022).
Garland, E. L. et al. Mindfulness-oriented recovery enhancement for veterans and military personnel on long-term opioid therapy for chronic pain: a randomized clinical trial. Am. J. Psychiatry 181, 125–134 (2024).
Cooperman, N. A. et al. Telehealth mindfulness-oriented recovery enhancement vs usual care in individuals with opioid use disorder and pain: a randomized clinical trial. JAMA Psychiatry 81, 338–346 (2024).
Cooperman, N. A., Hanley, A. W., Kline, A. & Garland, E. L. A pilot randomized clinical trial of mindfulness-oriented recovery enhancement as an adjunct to methadone treatment for people with opioid use disorder and chronic pain: Impact on illicit drug use, health, and well-being. J. Subst. Abuse Treat. 127, 108468 (2021).
Garland, E. L. Mindful positive emotion regulation as a treatment for addiction: from hedonic pleasure to self-transcendent meaning. Curr. Opin. Behav. Sci. 39, 168–177 (2021).
Garland, E. L., Hanley, A. W., Hudak, J., Nakamura, Y. & Froeliger, B. Mindfulness-induced endogenous theta stimulation occasions self-transcendence and inhibits addictive behavior. Sci. Adv. 8, eabo4455 (2022).
Hudak, J. et al. Endogenous theta stimulation during meditation predicts reduced opioid dosing following treatment with mindfulness-oriented recovery enhancement. Neuropsychopharmacology 46, 836–843 (2021).
Rothberg, R. L., Azhari, N., Haug, N. A. & Dakwar, E. Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: results from a randomized, controlled trial. J. Psychopharmacol. 35, 150–158 (2021).
Dakwar, E. et al. Therapeutic infusions of ketamine: do the psychoactive effects matter?. Drug Alcohol Depend. 136, 153–157 (2014).
Dakwar, E. et al. A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: results from a randomized, controlled laboratory study. Neuropharmacology 142, 270–276 (2018).
Sacchet, M. D., Fava, M. & Garland, E. L. Modulating self-referential processing through meditation and psychedelics: is scientific investigation of self-transcendence clinically relevant?. World Psychiatry 23, 298 (2024).
Bahji, A., Zarate, C. A. & Vazquez, G. H. Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. Expert Opin. Drug Saf. 21, 853–866 (2022).
Williams, N. R. et al. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Mol. Psychiatry 24, 1779–1786 (2019).
Levinstein, M. R. et al. Mu opioid receptor activation mediates (S)-ketamine reinforcement in rats: implications for abuse liability. Biol. Psychiatry 93, 1118–1126 (2023).
Barrett, F. S., Johnson, M. W. & Griffiths, R. R. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J. Psychopharmacol. 29, 1182–1190 (2015).
Das, R. K. et al. Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories. Nat. Commun. 10, 5187 (2019).
Marks, M. Psychedelic therapy scrutinized by FDA Advisory Committee?. JAMA 332, 963–964 (2024).
Lappan, S. N., Brown, A. W. & Hendricks, P. S. Dropout rates of in-person psychosocial substance use disorder treatments: a systematic review and meta-analysis. Addiction 115, 201–217 (2020).
Krupitsky, E. et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 377, 1506–1513 (2011).
Rudolph, K. E. et al. Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder. Drug Alcohol Depend. 239, 109609 (2022).
Hanley, A. W. et al. The Metacognitive Processes of Decentering Scale: development and initial validation of trait and state versions. Psychol. Assess. 32, 956 (2020).
Hanley, A. W. & Garland, E. L. The Mindfulness-Oriented Recovery Enhancement Fidelity Measure (MORE-FM): development and validation of a new tool to assess therapist adherence and competence. J. Evid. Based. Soc. Work 18, 308–322 (2021).
Dakwar, E. et al. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. Am. J. Psychiatry 177, 125–133 (2020).
Kolp, E. et al. Ketamine psychedelic psychotherapy: focus on its pharmacology, phenomenology, and clinical applications. Int. J. Transpers. Stud. https://doi.org/10.24972/ijts.2014.33.2.84 (2014).
Sobell, L. C. & Sobell, M. B. in Measuring Alcohol Consumption (eds Litten, R. Z. & Allen, J. P.) 41–72 (Springer, 1992).
Franken, I. H., Hendriksa, V. M. & van den Brink, W. Initial validation of two opiate craving questionnaires the obsessive compulsive drug use scale and the desires for drug questionnaire. Addict. Behav. 27, 675–685 (2002).
Lovibond, S. H. & Lovibond, P. F. Manual for the Depression Anxiety Stress Scales (Psychology Foundation, 1995).
Hanley, A. W., Nakamura, Y. & Garland, E. L. The Nondual Awareness Dimensional Assessment (NADA): new tools to assess nondual traits and states of consciousness occurring within and beyond the context of meditation. Psychol. Assess. 30, 1625 (2018).
Liu, G. F., Lu, K., Mogg, R., Mallick, M. & Mehrotra, D. V. Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?. Stat. Med. 28, 2509–2530 (2009).
Little, R. J. & Rubin, D. B. Statistical Analysis with Missing Data (John Wiley & Sons, 2019); https://doi.org/10.1002/9781119482260